The role of PARP inhibitors in
BRCA
PARP inhibitors
niraparib
olaparib
pancreatic cancer
rucaparib
talazoparib
veliparib
Journal
Therapeutic advances in gastroenterology
ISSN: 1756-283X
Titre abrégé: Therap Adv Gastroenterol
Pays: England
ID NLM: 101478893
Informations de publication
Date de publication:
2021
2021
Historique:
received:
15
12
2020
accepted:
14
04
2021
entrez:
24
5
2021
pubmed:
25
5
2021
medline:
25
5
2021
Statut:
epublish
Résumé
Pancreatic ductal adenocarcinoma (PDAC) accounts for about 3% of all cancers in the United States and about 7% of all cancer deaths. Despite the lower prevalence relative to other solid tumors, it is one of the leading causes of cancer-related death in the US. PDAC is highly resistant to chemotherapy as well as radiation therapy. Current standard-of-care chemotherapeutic regimens provide transient disease control but eventually tumors develop chemoresistance. Tumors that are deficient in DNA damage repair mechanisms such as
Identifiants
pubmed: 34025781
doi: 10.1177/17562848211014818
pii: 10.1177_17562848211014818
pmc: PMC8120537
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
17562848211014818Informations de copyright
© The Author(s), 2021.
Déclaration de conflit d'intérêts
Conflict of interest statement: The authors declare that there is no conflict of interest.
Références
Clin Cancer Res. 2020 Oct 1;26(19):5092-5101
pubmed: 32669374
Cancer Res. 2016 May 1;76(9):2778-90
pubmed: 27197267
Clin Cancer Res. 2017 Jun 15;23(12):3097-3108
pubmed: 27993965
Genes Dev. 2017 Feb 1;31(3):318-332
pubmed: 28242626
J Natl Compr Canc Netw. 2020 Nov 02;18(11):1528-1536
pubmed: 33152708
N Engl J Med. 2018 Dec 27;379(26):2495-2505
pubmed: 30345884
N Engl J Med. 2017 Aug 10;377(6):523-533
pubmed: 28578601
Am J Transl Res. 2020 Feb 15;12(2):612-617
pubmed: 32194909
J Clin Oncol. 2020 May 1;38(13):1378-1388
pubmed: 31976786
N Engl J Med. 2013 Oct 31;369(18):1691-703
pubmed: 24131140
N Engl J Med. 2018 Aug 23;379(8):753-763
pubmed: 30110579
Oncotarget. 2016 Oct 4;7(40):65982-65992
pubmed: 27602757
Lancet. 2017 Oct 28;390(10106):1949-1961
pubmed: 28916367
Lancet Oncol. 2019 May;20(5):636-648
pubmed: 30948273
J Clin Invest. 2015 Sep;125(9):3365-76
pubmed: 26325033
Mol Oncol. 2011 Aug;5(4):387-93
pubmed: 21821475
J Exp Med. 2017 Mar 6;214(3):579-596
pubmed: 28232471
N Engl J Med. 2016 Dec;375(22):2154-2164
pubmed: 27717299
N Engl J Med. 2009 Jul 9;361(2):123-34
pubmed: 19553641
Lancet. 2017 Mar 11;389(10073):1011-1024
pubmed: 28129987
Cell Rep. 2018 Apr 3;23(1):100-111
pubmed: 29617652
Mol Cell Biol. 2007 Aug;27(15):5597-605
pubmed: 17548475
N Engl J Med. 2011 May 12;364(19):1817-25
pubmed: 21561347
Nat Rev Drug Discov. 2020 Oct;19(10):711-736
pubmed: 32884152
J Gastrointest Surg. 2006 Nov;10(9):1199-210; discussion 1210-1
pubmed: 17114007
Pancreas (Fairfax). 2019;3(1):e5-e8
pubmed: 32030362
Cancer Res. 2014 Jun 1;74(11):2913-21
pubmed: 24840647
Mol Cell. 2018 Jul 19;71(2):319-331.e3
pubmed: 29983321
Front Cell Dev Biol. 2020 Sep 09;8:564601
pubmed: 33015058
Eur J Cancer. 2018 Jan;89:19-26
pubmed: 29223478
Cancer Epidemiol Biomarkers Prev. 2007 Feb;16(2):342-6
pubmed: 17301269
N Engl J Med. 2019 Jul 25;381(4):317-327
pubmed: 31157963
Cancer Manag Res. 2019 May 10;11:4371-4390
pubmed: 31191001
JAMA. 2018 Jun 19;319(23):2401-2409
pubmed: 29922827
Oncoimmunology. 2013 Jul 1;2(7):e24891
pubmed: 24073373
Clin Cancer Res. 2014 Feb 1;20(3):540-7
pubmed: 24270682
Lancet Oncol. 2017 Jan;18(1):75-87
pubmed: 27908594
J Clin Oncol. 2016 Jul 20;34(21):2541-56
pubmed: 27247221
Cancer Discov. 2015 Nov;5(11):1137-54
pubmed: 26463832
Nat Rev Cancer. 2011 Dec 23;12(1):68-78
pubmed: 22193408
Nat Rev Cancer. 2016 Feb;16(2):110-20
pubmed: 26775620
Br J Cancer. 2014 Sep 9;111(6):1132-8
pubmed: 25072261
J Natl Cancer Inst. 2016 Jul 05;108(11):
pubmed: 27381626
Gut. 2015 Sep;64(9):1476-84
pubmed: 25994217
N Engl J Med. 2020 May 28;382(22):2091-2102
pubmed: 32343890
J Clin Oncol. 2020 Nov 10;38(32):3763-3772
pubmed: 32795228
Lancet Oncol. 2017 Sep;18(9):1274-1284
pubmed: 28754483